Beijing Tricision Therapeutics

Tricision Therapeutics is a clinical-stage biotechnology company headquartered in Beijing, China, focused on discovering and developing innovative multi-specific antibody therapies for oncology. The company utilizes its proprietary Tri-Specific T-cell Engager (TriTE) platform to engineer antibodies that can simultaneously bind to multiple tumor antigens and T-cells. This approach aims to improve therapeutic efficacy and safety over existing bispecific formats by enhancing tumor selectivity and reducing off-target effects. Its lead program, TSW001, is a first-in-class tri-specific antibody targeting CD3, CD19, and CD20, currently undergoing Phase 1 clinical trials for B-cell hematological malignancies. Tricision's pipeline also includes TSW011, targeting BCMA and CD38 for multiple myeloma, alongside several undisclosed programs for solid tumors. The company is supported by a strong syndicate of life science investors, including Qiming Venture Partners and Lilly Asia Ventures. Tricision aims to leverage its platform to address unmet medical needs in both liquid and solid tumors globally.